Swan Global Investments LLC Sells 20,123 Shares of Cibus, Inc. (NASDAQ:CBUS)

Swan Global Investments LLC cut its holdings in Cibus, Inc. (NASDAQ:CBUS) by 57.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 15,000 shares of the company’s stock after selling 20,123 shares during the period. Swan Global Investments LLC’s holdings in Cibus were worth $42,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its position in Cibus by 16.9% in the 3rd quarter. FMR LLC now owns 3,913,279 shares of the company’s stock valued at $12,757,000 after acquiring an additional 566,328 shares in the last quarter. Wellington Management Group LLP purchased a new stake in Cibus during the 3rd quarter valued at $111,000. Charles Schwab Investment Management Inc. raised its stake in Cibus by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock valued at $161,000 after buying an additional 6,276 shares during the last quarter. IFP Advisors Inc purchased a new stake in Cibus during the 4th quarter valued at $36,000. Finally, State Street Corp raised its stake in Cibus by 43.6% during the 3rd quarter. State Street Corp now owns 307,262 shares of the company’s stock valued at $1,002,000 after buying an additional 93,236 shares during the last quarter. 33.81% of the stock is owned by institutional investors.

Cibus Price Performance

NASDAQ:CBUS opened at $2.05 on Friday. The firm has a market capitalization of $54.23 million, a price-to-earnings ratio of -0.09 and a beta of 2.04. Cibus, Inc. has a one year low of $1.80 and a one year high of $23.18. The business has a fifty day moving average price of $2.33 and a 200-day moving average price of $3.33.

Cibus (NASDAQ:CBUS) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.19). The company had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $1.13 million. Cibus had a negative return on equity of 28.17% and a negative net margin of 10,724.78%. On average, equities research analysts expect that Cibus, Inc. will post -2.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CBUS. Canaccord Genuity Group decreased their target price on shares of Cibus from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Cibus in a research note on Friday.

Cibus Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.